

Economic Burden of Cytopenia in Patients with Myelofibrosis: Analysis of a US National Administrative Claims Database

PS2295

Aaron T. Gerds<sup>1</sup>, Lucia Masarova<sup>2</sup>, Nicole M. Engel-Nitz<sup>3</sup>, Michael Marrone<sup>4</sup>, Jeffrey McPheeters<sup>3</sup>, Abiola, Oladapo<sup>4</sup>, Purvi Suthar<sup>4</sup>, Michael Vredenburg<sup>4</sup>, Yong Zhu<sup>3</sup>, Lindsay Rein<sup>5</sup>

<sup>1</sup> Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, United States of America, <sup>2</sup> The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, TX, United States of America, <sup>3</sup> Optum, Eden Prairie, MN, United States of America, <sup>4</sup> Sobi Inc., Waltham, MA, United States of America, <sup>5</sup> Duke Health, Durham, NC, United States of America

CONCLUSIONS

- Healthcare resource utilization (HCRU) and costs were significantly higher in patients with cytopenic myelofibrosis (MF).
- Use of appropriate MF treatments with an ideal mechanism to manage cytopenia may reduce the overall burden of disease to patients and the healthcare system.

BACKGROUND

- Cytopenic myelofibrosis (MF) is characterized by the presence of anemia and/or thrombocytopenia, which may be present at diagnosis or develop over the course of the disease.<sup>1</sup>
- Cytopenic MF is associated with worse clinical prognosis and a higher risk of mortality than non-cytopenic MF.<sup>2</sup> However, little is known about the economic burden of cytopenia in patients with MF.


AIM

- To describe healthcare resource utilization (HCRU) and costs in patients with cytopenic MF compared to MF patients without cytopenia in the United States.

METHODS

Study Design

- This retrospective study included adult patients diagnosed with MF (ICD-10 codes D75.81 and D47.4) from July 2016 to April 2023 using administrative claims data from the Optum Research Database.
- Patients were required to be continuously enrolled in insurance plans for ≥6 months before diagnosis (baseline period) and ≥12 months after diagnosis, unless they died within 12 months (follow-up period) (Figure 1).
- Cytopenia was defined as a diagnosis of anemia or thrombocytopenia in claims within 30 days before or after diagnosis of MF, or prior to the start of systemic anti-cancer treatment if the treatment was initiated within 30 days of MF diagnosis.



Study Outcomes

- All-cause HCRU and costs in baseline and follow-up periods, as well as MF-related HCRU and costs in the follow-up period were reported as per-patient-per-month; costs were CPI adjusted to 2023 USD.

Analyses

- Chi-square or t-tests were used to compare differences by cytopenic status. P<0.05 was significant.

RESULTS

Table 1: Baseline Demographic and Clinical Characteristics

	Total (N=1,532)	Cytopenia (N=1,074)	No Cytopenia (N=458)	p-value†
Age, mean (SD)	72.4 (11.4)	73.9 (10.7)	68.9 (12.0)	<0.001
Age group, n (%)				
18-44	43 (2.8)	22 (2.1)	21 (4.6)	0.006
45-64	248 (16.2)	135 (12.6)	113 (24.7)	<0.001
65+	1,241 (81.0)	917 (85.4)	324 (70.7)	<0.001
Gender, n (%)				
Female	713 (46.5)	486 (45.3)	227 (49.6)	0.121
Male	819 (53.5)	588 (54.8)	231 (50.4)	0.121
Region, n (%)				
Northeast	281 (18.3)	196 (18.3)	85 (18.6)	0.886
Midwest	384 (25.1)	266 (24.8)	118 (25.8)	0.680
South	661 (43.2)	475 (44.2)	186 (40.6)	0.191
West*	206 (13.5)	137 (12.8)	69 (15.1)	0.225
Insurance type, n (%)				
Commercial	308 (20.1)	170 (15.9)	138 (30.1)	<0.001
Medicare Advantage	1,224 (80.0)	904 (84.2)	320 (69.9)	<0.001
Quan-Charlson comorbidity score, mean (SD)	1.9 (2.1)	2.2 (2.2)	1.2 (1.6)	<0.001

Notes: \*Includes n<5 patients with Other geographic region.  
† P-values were calculated using chi-square tests for categorical variables and independent t-tests for continuous variables.

Study Population

- Of the 1,532 patients who met the study eligibility criteria, 1,074 (70%) were cytopenic at the time of MF diagnosis.

Patient Demographics and Clinical Characteristics

- Compared to patients who did not have cytopenia at MF diagnosis, patients with cytopenic MF were older and had higher baseline Charlson comorbidity score (Table 1).


Table 2: All-cause HCRU Counts at Baseline and Follow-up

	Baseline			Follow-up		
All-cause HCRU Counts (PPPM), mean (SD)	Cytopenia (N=1,074)	No Cytopenia (N=458)	p-value*	Cytopenia (N=1,074)	No Cytopenia (N=458)	p-value*
Ambulatory visit	3.7 (3.4)	2.8 (2.5)	<0.001	5.2 (4.2)	3.5 (2.9)	<0.001
Office visit	1.7 (1.6)	1.4 (1.4)	<0.001	1.9 (1.8)	1.6 (1.3)	<0.001
Outpatient visit	2.0 (2.8)	1.3 (2.0)	<0.001	3.3 (3.6)	2.0 (2.4)	<0.001
Emergency room visit	0.2 (0.3)	0.1 (0.2)	<0.001	0.4 (0.7)	0.2 (0.4)	<0.001
Inpatient admit	0.1 (0.1)	0.0 (0.1)	<0.001	0.2 (0.4)	0.1 (0.1)	<0.001
Pharmacy fill	3.1 (3.0)	2.6 (2.2)	<0.001	3.7 (2.7)	3.2 (2.3)	<0.001

Notes: \* P-values represent comparisons between cytopenia and non-cytopenia groups, assessed using independent t-tests.  
Abbreviation: PPPM, per-patient-per-month


All-cause HCRU at Baseline and Follow-up

- During both the baseline and follow-up periods, individuals with cytopenic MF had significantly higher all-cause HCRU including ambulatory visits, emergency room (ER) visits, hospitalizations, and pharmacy fills compared to those without cytopenia at diagnosis (p<0.001) (Table 2).



All-Cause Healthcare Costs at Baseline

- All-cause total healthcare cost in the baseline period was significantly higher in patients with cytopenic MF compared to patients without cytopenia (p<0.001) (Figure 2).



All-Cause Healthcare Costs during Follow-up

- All-cause total healthcare cost during the follow-up period was 53% higher for patients with cytopenia vs patients without cytopenia (\$12,826±20,395 vs \$8,360±10,897 PPPM, p<0.001) (Figure 3).


Table 3: MF-Related HCRU During Follow-up

MF-Related HCRU (PPPM), mean (SD)	Cytopenia (N=1,074)	No Cytopenia (N=458)	p-value
Ambulatory visit	1.31 (1.72)	0.76 (1.25)	<0.001
Office visit	0.41 (0.74)	0.24 (0.43)	<0.001
Outpatient visit	0.90 (1.48)	0.52 (1.10)	<0.001
Emergency room visit	0.05 (0.18)	0.03 (0.26)	0.172
Inpatient admission	0.12 (0.32)	0.04 (0.09)	<0.001
Length of stays (days)	2.67 (4.60)	1.30 (2.18)	<0.001
Pharmacy fill	0.33 (0.39)	0.39 (0.43)	0.003

Abbreviation: PPPM, per-patient-per-month

MF-Related HCRU during Follow-up

- Patients with cytopenic MF had 72% more MF-related ambulatory visits and 200% more hospitalizations, but fewer MF-related pharmacy fills compared to those without cytopenia (p=0.003) (Table 3).



MF-Related Healthcare Costs at Follow-up

- Patients with cytopenic MF had significantly higher MF-related total healthcare costs (43%) than patients without cytopenia (\$8,673±18,291 vs \$6,060±9.174; p<0.001) (Figure 4).

References

- Chifotides HT, Verstovsek S, Bose P. 2023. Cancers. 15:3331.
- Coltro G, Mannelli F, Loscocco GG, et al. 2022. Blood Cancer J. 12:116.

Disclosures and Acknowledgements

This study was funded by Swedish Orphan Biovitrum (Sobi Inc.). MM, AO, PS, and MV are Sobi Inc. employees. NE, JM, and YZ are Optum employees and UnitedHealth Group shareholders; Optum was contracted by Sobi Inc. to conduct the study. AG (Cleveland Clinic), LC (MD Anderson), and LR (Duke Health) received Sobi Inc. funding. The poster was developed per GPP 2022 guidelines (<https://www.ismpp.org/gpp-2022>). Sobi Inc. reviewed the content; authors retained full editorial control and approved the final version. Medical writing support was provided by Daryl Truong, PharmD (Optum).

Copies obtained through the QR Code are for personal use only. The hosting website is non-promotional and global, and it may include information not applicable to your country. Always refer to your local prescribing information